A tailored biomimetic strategy involving myeloid cells in vitro and in vivo lowering cholesterol levels prevented PCa EV uptake by recipient myeloid cells, eliminated NF-κB activity, maintained thrombospondin-1 expression, decreased osteoclast differentiation, and yielded a 77% reduction in metastatic burden[100]. Here, NFKB1 is linked to posterior cortical atrophy.